Abstract
Non-hepatic delivery of small interfering RNA (siRNA) remains a challenge for the development of RNA interference (RNAi)-based therapeutics. Inhalation is a straightforward and highly efficient route of delivering drugs to airways and pulmonary parenchyma, thus offering an opportunity for the novel paradigm of siRNA to treat lung diseases. Herein, we designed a fullerene-based nanocomplex to achieve the pulmonary delivery of siRNA via inhalation. The obtained nanocomplex protects encapsulated siRNA against nucleases degradation, improves the cellular uptake and gene knockdown efficiency, and prolongs the pulmonary retention of siRNA after inhalation. Through the package of programmed death-ligand 1 (PD-L1) siRNA, this nanocomplex significantly inhibits the progression of metastatic lung cancer without obvious adverse events and toxicity in a mouse model. This fullerene-based nanocomplex could open up the possibility of siRNA for treating a diverse range of pulmonary diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
